WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
Pharmaceutical Statistics · 2025-03 · 24 (2)
DOI: 10.1002/pst.2463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 26.12.2024. Verfasst von Konstantinos Sechidis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Workflow, Drug Development, Randomized Controlled Trials as Topic, Research Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Novartis Pharma.
Abstract (Originalsprache)
This article proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address the challenges of investigating treatment effect heterogeneity (TEH) in randomized clinical trials, where sample size and multiplicity limit the reliability of findings. The proposed workflow includes four steps: analysis planning, initial data analysis and analysis dataset creation, TEH exploration, and multidisciplinary assessment. The workflow offers a general overview of how treatment effects vary by baseline covariates in the observed data and guides the interpretation of the observed findings based on external evidence and the best scientific understanding. The workflow is exploratory and not inferential/confirmatory in nature but should be preplanned before database lock and analysis start. It is focused on providing a general overview rather than a single specific finding or subgroup with a differential effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
- Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- Department of Biostatistics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
- China Novartis Institutes for Bio-Medical Research Co, Shanghai, China.
- Development Analytics and Statistical Innovation, UCB Farchim SA, Bulle, Switzerland.
- Consilium Hemmings (UK) Ltd, Woking, UK.
ORCID-Profile: Konstantinos Sechidis, Marc Vandemeulebroecke, Stephen Ruberg, Björn Bornkamp
Förderung
- Novartis Pharma
Zitieren
APA
Sechidis, K., Sun, S., Chen, Y., Lu, J., Zhang, C., Baillie, M., Ohlssen, D., Vandemeulebroecke, M., Hemmings, R., Ruberg, S., & Bornkamp, B. (2025). WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors. Pharmaceutical Statistics, 24(2). https://doi.org/10.1002/pst.2463
Vancouver
Sechidis K, Sun S, Chen Y, Lu J, Zhang C, Baillie M, et al. WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors. Pharmaceutical Statistics. 2025;24(2). doi:10.1002/pst.2463
BibTeX
@article{Sechidis2025,
author = {Sechidis, Konstantinos and Sun, Sophie and Chen, Yao and Lu, Jiarui and Zhang, Cong and Baillie, Mark and Ohlssen, David and Vandemeulebroecke, Marc and Hemmings, Rob and Ruberg, Stephen and Bornkamp, Björn},
title = {WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors},
journal = {Pharmaceutical Statistics},
year = {2025},
volume = {24},
number = {2},
doi = {10.1002/pst.2463}
}
EUVIMED